Interim report January-March 2018

2018-05-08

Vicore Pharma Holding (publ) (ticker: VICO) publish the interim report for the first quarter 2018.

IMPORTANT EVENTS DURING THE FIRST QUARTER

  • In February, Vicore Pharma Holding acquired additional shares from an existing shareholder in I-Tech. As such, our holding amounted to 26.5%. In March, I-Tech issued shares to a new shareholder, Cambrex Karlskoga AB. Vicore Pharma Holding’s holding is consequently 21.2%.

IMPORTANT EVENTS AFTER THE PERIOD

  • In April Vicore Pharma holds approval from the UK authorities and the Ethics Committee to initiate a Phase IIa Study on Idiopathic Pulmonary Fibrosis (IPF)

FINANCIAL SUMMARY (GROUP)

KSEK  Jan-Mar 2018  Jan-Mar 2017  Year
2017 
Year
2016 
Operating profit/loss  -4 235  -2 456  -12 793   -6 649 
Profit/loss after financial items  4 257  -2 514  -12 855  -6 652 
Earnings per share, SEK  0,27  -0,16  -0,81  -0,54 
Equity as per end of period  117 226  101 928   112 969   75 597  
Cash flow from operating activities  -2 261  -2 474   -7 703   -7 289  
Cash flow from investing activities  -7 649  -3 613   -22 780   -13 940  
Cash and cash equivalents as of end of period  13 744  27 024   24 019   4 266  

For more information, please contact:

Hans Jeppsson, CFO
M: +46 (0)70 553 14 65

hans.jeppsson@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 09.00 CET on May 8, 2018

  • Interim report, Q1 2018